Skip to main content
OpenTrials

Clinical trial condition

Blood-Borne Infections

Explore clinical trials studying Blood-Borne Infections. Study availability and eligibility vary by location and protocol.

8,277 public trials 443 recruiting studies
Refine in advanced search Browse all conditions

Blood-Borne Infections trial results

Completed

A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus

NCT01724086

Conditions
Blood-Borne Infections, Chronic Disease, Chronic Hepatitis C, +15 more
Locations
  • Antwerp, Belgium
  • Bruges, Belgium
  • Brussels, Belgium
  • Edegem, Belgium
View Trial Details
Completed

A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.

NCT00905489

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • 1100.1518.0001 Boehringer Ingelheim Investigational Site Washington D.C., District of Columbia, United States
  • 1100.1518.0002 Boehringer Ingelheim Investigational Site Philadelphia, Pennsylvania, United States
  • 1100.1518.2605 Boehringer Ingelheim Investigational Site Francistown, Botswana
  • 1100.1518.2601 Boehringer Ingelheim Investigational Site Gaborone, Botswana
View Trial Details
Completed

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.

NCT01328041

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Beverly Hills, California, United States
  • GSK Investigational Site Fountain Valley, California, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Los Angeles, California, United States
View all 89 locations
View Trial Details
Completed

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

NCT01495702

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +13 more
Locations
  • Spectrum Medical Group Phoenix, Arizona, United States
  • AHF Research Center Beverly Hills, California, United States
  • Pacific Oak Medical Group Beverly Hills, California, United States
  • Kaiser Permanente Hayward, California, United States
View all 80 locations
View Trial Details

Related conditions